Fate Therapeutics

NASDAQ

FATE

Stock

Yield per half year: -56.72%
Dividend yield: 0%
Sector: Healthcare

News

Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors - Neurocrine Biosciences ( NASDAQ:NBIX ) , Fate Therapeutics ( NASDAQ:FATE )

30 may 20:30 Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors - Neurocrine Biosciences ( NASDAQ:NBIX ) , Fate Therapeutics ( NASDAQ:FATE )

Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors

30 may 20:30 Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors